Piper Sandler Raises Envista (NYSE:NVST) Price Target to $18.00

Envista (NYSE:NVST - Get Free Report) had its target price upped by equities researchers at Piper Sandler from $17.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Piper Sandler's target price points to a potential downside of 16.98% from the stock's previous close.

Several other brokerages have also issued reports on NVST. Leerink Partnrs raised shares of Envista from a "strong sell" rating to a "hold" rating in a report on Thursday, October 31st. Stifel Nicolaus upped their price target on shares of Envista from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday, October 23rd. Jefferies Financial Group raised their price objective on Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Mizuho assumed coverage on Envista in a report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 target price for the company. Finally, Wells Fargo & Company started coverage on shares of Envista in a research report on Tuesday, October 8th. They issued an "equal weight" rating and a $20.00 price target for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $20.21.

Envista Stock Performance

NVST stock traded up $1.11 during trading hours on Monday, hitting $21.68. 4,816,076 shares of the stock were exchanged, compared to its average volume of 2,181,582. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $3.73 billion, a P/E ratio of -2.77, a P/E/G ratio of 1.82 and a beta of 1.34. Envista has a 12 month low of $15.15 and a 12 month high of $24.79. The company has a 50-day simple moving average of $19.97 and a two-hundred day simple moving average of $19.10.

Envista (NYSE:NVST - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. On average, analysts forecast that Envista will post 0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Amalgamated Bank raised its position in Envista by 0.7% in the fourth quarter. Amalgamated Bank now owns 80,380 shares of the company's stock worth $1,551,000 after acquiring an additional 523 shares during the period. GAMMA Investing LLC raised its stake in shares of Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after buying an additional 538 shares during the period. M&T Bank Corp lifted its position in shares of Envista by 4.2% during the 4th quarter. M&T Bank Corp now owns 16,621 shares of the company's stock valued at $320,000 after buying an additional 676 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company's stock worth $43,000 after acquiring an additional 728 shares during the period. Finally, Blue Trust Inc. increased its stake in shares of Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company's stock worth $39,000 after purchasing an additional 804 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.